INDICATION & LIMITATION OF USE
DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.
Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.
Please see below for Important Safety Information for DESCOVY.
PrEP is a key prevention strategy in addressing the HIV epidemic1
PrEP is highly effective for preventing HIV2,3
According to the CDC, PrEP (pre-exposure prophylaxis) can reduce the chance of contracting HIV from sex, when taken as prescribed. However, uptake of PrEP medication in the United States remains low despite significant potential for HIV acquisition.
Only
36%
of the 1.2M people indicated for PrEP in 2022
were prescribed a PrEP medication4
(CDC, 2022 US estimates for individuals aged ≥16 years)
Learn more about the impact of PrEP on new HIV diagnoses
Opportunity for increased HIV prevention and PrEP discussions spans across several populations
Black MSM4,5
Higher lifetime risk of HIV diagnosis
1in2
Black MSM*
vs 1 in 11 White MSM
*CDC estimates based on HIV diagnosis and death rates from 2010-2014.
Disparity in PrEP uptake:
13%
of 468,540
Black
individuals
were prescribed
a PrEP medication in 2022
vs 94% of 300,650 White individuals
(CDC, 2022 estimates for individuals aged ≥16 years who were PrEP eligible)
*CDC estimates based on HIV diagnosis and death rates from 2010-2014.
(CDC, 2022 estimates for individuals aged ≥16 years who were PrEP eligible)
Latinx/o MSM4,5
Higher lifetime risk of HIV diagnosis
1in5
Latinx/o MSM*
vs 1 in 11 White MSM
*CDC estimates based on HIV diagnosis and death rates from 2010-2014.
Disparity in PrEP uptake:
24%
of 312,820 Latinx/o individuals
were prescribed
a PrEP medication in 2022
vs 94% of 300,650 White individuals
(CDC, 2022 estimates for individuals aged ≥16 years who were PrEP eligible)
*CDC estimates based on HIV diagnosis and death rates from 2010-2014.
(CDC, 2022 estimates for individuals aged ≥16 years who were PrEP eligible)
Young MSM4,6
Among HIV diagnoses in 2021
~3in5
were MSM aged
13-34 years
(64%; CDC, 2021 HIV estimates for MSM; N=24,107)
Disparity in PrEP uptake:
34%
of 680,970 individuals aged 16-34 years
were prescribed
a PrEP medication in 2022
(CDC, 2022 estimates for individuals who were PrEP eligible)
(64%; CDC, 2021 HIV estimates for MSM; N=24,107)
(CDC, 2022 estimates for individuals who were PrEP eligible)
Transgender women (TGW)7,8
A meta-analysis of 98 studies showed:
TGW 66x
more
likely
to have HIV vs other individuals (aged >15 years)
(Stutterheim SE, et al; 2021; N=48,604)
A 2019-2020 study showed low PrEP uptake:
32%
of HIV-negative TGW (n=288/902)
were on a PrEP medication
(CDC, National HIV Behavioral Surveillance report in 7 US cities)
(Stutterheim SE, et al; 2021; N=48,604)
(CDC, National HIV Behavioral Surveillance report in 7 US cities)
Hear from experts on the role PrEP plays in communities most vulnerable and affected by HIV
PrEP Use in the Black Community
Learn more about reframing HIV prevention and emphasizing its importance to sexual health in the Black community.
PrEP Use in the Latinx/o Community
Learn more about helping to address barriers to PrEP uptake in the Latinx/o community.
PrEP Use in Young MSM
Learn more about engaging and educating young men on HIV prevention.
Help end the HIV epidemic by championing discussions about HIV prevention options today.
CDC=Centers for Disease Control and Prevention; MSM=men who have sex with men; TGW=transgender women (who have sex with men).